APA

Wikman H., Thiel S., Jäger B., Schmezer P., Spiegelhalder B., Edler L., Dienemann H., Kayser K., Schulz V., Drings P., Bartsch H. & Risch A. (20010614). Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. : Pharmacogenetics.

Chicago

Wikman H, Thiel S, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H and Risch A. 20010614. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. : Pharmacogenetics.

Harvard

Wikman H., Thiel S., Jäger B., Schmezer P., Spiegelhalder B., Edler L., Dienemann H., Kayser K., Schulz V., Drings P., Bartsch H. and Risch A. (20010614). Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. : Pharmacogenetics.

MLA

Wikman H, Thiel S, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H and Risch A. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. : Pharmacogenetics. 20010614.